Alerts will be sent to your verified email
Verify Email
EMMESSA
|
Emmessar Biotech&Nut
|
Parmax Pharma
|
Venmax Drugs&Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
13.7 % | -1624.87 % | -44.32 % |
|
5yr average Equity Multiplier
|
1.24 | 46.04 | -0.19 |
|
5yr Average Asset Turnover Ratio
|
0.36 | 0.95 | 0.32 |
|
5yr Avg Net Profit Margin
|
71.53 % | -9.48 % | -30.94 % |
|
Price to Book
|
1.82 | 0.0 | 3.42 |
|
P/E
|
34.72 | 0.0 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
68.18 Days | -161.05 Days | 0.0 |
|
Inventory Days
|
62.21 Days | 73.65 Days | 24.83 Days |
|
Days Receivable
|
10.88 Days | 40.27 Days | 0.0 |
|
Days Payable
|
199.95 Days | 328.05 Days | 189.56 Days |
|
5yr Average Interest Coverage Ratio
|
815.2 | 1.16 | -318.36 |
|
5yr Avg ROCE
|
19.97 % | -9.94 % | -45.33 % |
|
5yr Avg Operating Profit Margin
|
-101.39 % | 3.93 % | -50.41 % |
|
5 yr average Debt to Equity
|
0.0 | 17.42 | -0.64 |
|
5yr CAGR Net Profit
|
0.0 | n/a | n/a |
|
5yr Average Return on Assets
|
10.86 % | -6.43 % | 187.49 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
59.53 % | 30.8 % | 23.13 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
1.34 % | 0.0 | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Emmessar Biotech&Nut
|
Parmax Pharma
|
Venmax Drugs&Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|